News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Recent

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

This Scientist Is Building Custom Gene-Editing Tools

November 11, 2024

This Scientist Is Building Custom Gene-Editing Tools

November 11, 2024

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

The 2024 PharmaVoice 100

October 8, 2024

The 2024 PharmaVoice 100

October 8, 2024

All Stories

News

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

Press

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

News

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

Press

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

News

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

Press

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

News

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

Press

Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal

May 16, 2023

San Francisco Business Times

Read Now

News

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

Press

Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal

May 16, 2023

Seeking Alpha

Read Now

News

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

Press

Scribe pens $1.5B-plus CRISPR tech deal with Lilly

May 16, 2023

BioWorld

Read Now

News

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

August 5, 2024

BioSpace

Read Now

News

Future of Epigenetic Medicine

July 22, 2024

Dr. Bruce McCabe

Read Now

News

CRISPR 2.0, the Next Generation

June 21, 2024

The Aspen Institute

Read Now

News

CRISPR technology’s next wave: Eight companies to watch in 2024

June 20, 2024

Labiotech

Read Now

News

Top Five Privately Held Gene Editing Therapy Companies

May 31, 2024

Genetic Engineering & Biotechnology News

Read Now

News

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

May 22, 2024

Ropes & Gray

Read Now

Press

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Press

Scribe Therapeutics to Participate in Upcoming Conferences

September 12, 2024

Read Now

Press

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

Press

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Read Now

Press

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

January 3, 2024

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Read Now